MBIO Stock Overview
MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Canada, Australia, and New Zealand.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MindBio Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.07 |
| 52 Week High | CA$0.56 |
| 52 Week Low | CA$0.015 |
| Beta | 0 |
| 1 Month Change | 40.00% |
| 3 Month Change | 250.00% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| MBIO | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 27.3% | 26.2% | -1.1% |
| 1Y | n/a | 84.7% | 4.9% |
Return vs Industry: Insufficient data to determine how MBIO performed against the Canadian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MBIO performed against the Canadian Market.
Price Volatility
| MBIO volatility | |
|---|---|
| MBIO Average Weekly Movement | 43.3% |
| Pharmaceuticals Industry Average Movement | 15.1% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: MBIO's share price has been volatile over the past 3 months.
Volatility Over Time: MBIO's weekly volatility has increased from 35% to 43% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Justin Hanka | www.mindbiotherapeutics.com |
MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Canada, Australia, and New Zealand. The company engages in researching, developing, and testing microdosing of psychedelic substances as a potential treatment for the management of various mental health conditions, such as depression, anxiety, PTSD, panic disorder, chronic pain, and opiate addictions. Its LSD-microdosing is currently under Phase 2 clinical trials for the treatment of major depressive disorder and microdosing of LSD in late-stage cancer patients.
MindBio Therapeutics Corp. Fundamentals Summary
| MBIO fundamental statistics | |
|---|---|
| Market cap | CA$8.65m |
| Earnings (TTM) | -CA$3.51m |
| Revenue (TTM) | CA$176.60k |
52.7x
P/S Ratio-2.7x
P/E RatioIs MBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBIO income statement (TTM) | |
|---|---|
| Revenue | AU$197.42k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$197.42k |
| Other Expenses | AU$4.13m |
| Earnings | -AU$3.93m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.03 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,990.02% |
| Debt/Equity Ratio | -87.7% |
How did MBIO perform over the long term?
See historical performance and comparison